| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Erlotinib | gCSI | pan-cancer | AAC | 0.0058 | 0.9 |
| mRNA | Bortezomib | GDSC1000 | pan-cancer | AAC | -0.0056 | 0.9 |
| mRNA | ELCPK | CTRPv2 | pan-cancer | AAC | 0.0072 | 0.9 |
| mRNA | Repligen 136 | CTRPv2 | pan-cancer | AAC | -0.0042 | 0.9 |
| mRNA | BRD-K13185470 | CTRPv2 | pan-cancer | AAC | -0.15 | 0.9 |
| mRNA | AZD4547 | CTRPv2 | pan-cancer | AAC | -0.0039 | 0.9 |
| mRNA | TL-1-85 | GDSC1000 | pan-cancer | AAC | 0.0029 | 0.9 |
| mRNA | BRD-K84807411 | CTRPv2 | pan-cancer | AAC | -0.15 | 0.9 |
| mRNA | GNF-2 | GDSC1000 | pan-cancer | AAC | 0.0055 | 0.9 |
| mRNA | ML050 | CTRPv2 | pan-cancer | AAC | -0.0039 | 0.9 |